
Minghui Pharmaceutical Reports Positive Phase I/II Results for MHB018A
At the Endocrine Society’s annual meeting in Chicago, Minghui Pharmaceutical unveiled data showing its subcutaneous antibody MHB018A provides significant relief for both active and chronic thyroid eye disease. The drug demonstrated high response rates in reducing proptosis and diplopia, positioning it as a potential leader in the IGF-1R-targeted therapy market.


























